X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (645) 645
Book Review (115) 115
Publication (46) 46
Conference Proceeding (14) 14
Book Chapter (7) 7
Patent (6) 6
Book / eBook (5) 5
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (460) 460
humans (388) 388
oncology (347) 347
male (227) 227
melanoma (216) 216
female (203) 203
middle aged (164) 164
aged (143) 143
cancer (143) 143
adult (131) 131
animals (124) 124
melanoma - pathology (108) 108
melanoma - drug therapy (107) 107
surgery (102) 102
skin neoplasms - pathology (85) 85
prognosis (79) 79
isolated limb perfusion (75) 75
skin neoplasms - drug therapy (72) 72
aged, 80 and over (70) 70
immunology (69) 69
treatment outcome (69) 69
immunotherapy (66) 66
melanoma - mortality (66) 66
neoplasm staging (64) 64
malignant-melanoma (63) 63
tumor necrosis factor-alpha - administration & dosage (63) 63
melphalan (62) 62
rats (62) 62
cutaneous melanoma (61) 61
interferon-gamma (60) 60
melphalan - administration & dosage (60) 60
metastatic melanoma (56) 56
hematology, oncology and palliative medicine (54) 54
survival (53) 53
medicine & public health (52) 52
care and treatment (51) 51
chemotherapy, cancer, regional perfusion (51) 51
disease-free survival (51) 51
tnf-alpha (51) 51
antineoplastic agents - therapeutic use (50) 50
metastasis (49) 49
skin neoplasms - mortality (49) 49
melanoma - surgery (48) 48
chemotherapy (47) 47
sarcoma (47) 47
tumors (47) 47
melanoma - secondary (44) 44
review (44) 44
chemotherapy, cancer, regional perfusion - methods (43) 43
melanoma - therapy (43) 43
mice (43) 43
therapy (43) 43
abridged index medicus (42) 42
tumor-necrosis-factor (42) 42
research (41) 41
survival rate (41) 41
extremities (38) 38
surgical oncology (38) 38
health aspects (37) 37
lymphatic metastasis (37) 37
adjuvant therapy (36) 36
adolescent (36) 36
antineoplastic agents - administration & dosage (36) 36
analysis (35) 35
ipilimumab (34) 34
skin neoplasms - surgery (34) 34
survival analysis (34) 34
combined modality therapy (33) 33
follow-up studies (33) 33
sarcoma - drug therapy (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
interferon-alpha - therapeutic use (31) 31
lymph node excision (30) 30
retrospective studies (30) 30
time factors (30) 30
trial (30) 30
antineoplastic agents, alkylating - administration & dosage (29) 29
high-risk melanoma (29) 29
medicine, research & experimental (29) 29
chemotherapy, adjuvant (28) 28
clinical trials (28) 28
combination (28) 28
factor-alpha (28) 28
interferon (28) 28
metastases (27) 27
pharmacology & pharmacy (27) 27
sentinel lymph node biopsy (27) 27
biopsy (26) 26
prognostic-factors (26) 26
risk factors (26) 26
young adult (26) 26
neoplasm metastasis (25) 25
expression (24) 24
melanoma - immunology (24) 24
clinical trials as topic (23) 23
kaplan-meier estimate (23) 23
skin neoplasms - therapy (23) 23
antibodies, monoclonal - therapeutic use (22) 22
antineoplastic agents - pharmacology (22) 22
breast-cancer (22) 22
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 101 - 105
The spectacular outcomes of the phase III trials regarding nivolumab versus ipilimumab in fully resected stage IIIB/C–IV and of the combination of dabrafenib... 
Nivolumab | Ipilimumab | Melanoma | Dabrafenib | Randomised trials | Adjuvant therapy | Trametinib | RANDOMIZED-TRIALS | COMPLETE RESECTION | PHASE-III TRIAL | INTERFERON-ALPHA | ANTI-PD-1 THERAPY | ONCOLOGY | TUMOR BURDEN | CUTANEOUS MELANOMA | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | ROTTERDAM CRITERIA | Antineoplastic Agents, Immunological - administration & dosage | Predictive Value of Tests | Skin Neoplasms - drug therapy | Humans | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Practice Patterns, Physicians | Patient Selection | Pyridones - administration & dosage | Time Factors | Skin Neoplasms - mortality | Clinical Decision-Making | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Ipilimumab - administration & dosage | Skin Neoplasms - pathology | Risk Factors | Treatment Outcome | Melanoma - pathology | Evidence-Based Medicine | Randomized Controlled Trials as Topic | Interferons - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Pyrimidinones - administration & dosage | Neoplasm Staging | Melanoma - mortality | Care and treatment | Oncology, Experimental | Interferon | Research | Biological response modifiers | Cancer | Risk groups | Toxicity | Decision making | Clinical trials | Exploration | Cancer therapies | Patients | Survival | Clinical outcomes | Lymph nodes | Risk management | Lymph | Index Medicus
Journal Article
Journal Article
by Eggermont, Alexander M. M and Suciu, Stefan and Santinami, Mario and Testori, Alessano and Kruit, Wim H. J and Marsden, Jeremy and Punt, Cornelis J. A and Salès, François and Gore, Martin and Mackie, Rona and Kusic, Zvonko and Dummer, Reinhard and Hauschild, Axel and Musat, Elena and Spatz, Alain and Keilholz, Ulrich and Salès, F and Baurain, J. F and Vereecke, P and Thomas, J and Verschaeve, V and Ollivaud, L and Aubin, F and Leccia, M. T and Avril, M. F and Robert, C and Negrier, S and Guillot, B and Dereure, O and Lipsker, D and Delaunay, M and Geoffrois, L and Vilmer-Renaud, C and Piette, F and Lesimple, T and Truchetet, F and Cupissol, D and Beylot-Barry, M and Bedane, C and Lacour, J. P and Machet, L and Cambazar, F and Perrot, J and Saiag, P and Vreugdenhil, G and Groenewegen, G and van den Eertwegh, A and Osanto, S and Ortiz-Romero, P. L and Castel Rodo, T and Mayordomo Camara, J. I and Bieber, T and Gollnick, H and Kleeberg, U and Scharffetter, K and Schneider, L and Schadendorf, D and Neuber, K and Eichhorn, K and Neumann, C and Emmert, S and Becker, J and Naher, H and Siegel, R and Tilgen, W and Kaempgen, E and Herbst, R and Frosch, P and Dummer, R and Fey, M and Ochsenbein, A and Lejeune, F and Lienard, D and Ziobro, M and Murawa, P and Oliver, R. T. D and Shamash, J and Mcaleer, J and Rankin, E. M and Selby, P. J and Ottensmeier, C and Maraveya, A and Hancock, B and Lorigan, P and Gore, M and Eisen, T and Harris, A and Barber, J and Corrie, P and MacKie, R and Steward, W. P and Marshall, E and Kelly, C and Price, C and Farrugia, D and Marsden, J and Dalgleish, A and Lamont, A and Szlosare, P and Houston, S and ... and EORTC Melanoma Grp and EORTC Melanoma Group
Lancet, ISSN 0140-6736, 2008, Volume 372, Issue 9633, pp. 117 - 126
Journal Article
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 4/2014, Volume 21, Issue 4, pp. 1075 - 1081
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 04/2006, Volume 98, Issue 7, pp. 472 - 482